person · Reporting owner

Kamdar Kim P.

Disclosed activity across 8 companies

Tapewire entity: 30494
SEC CIK: 0001535065

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Bionano Genomics, Inc.BNGO · Entity 7831	10% owner	August 21, 2018	August 21, 2018
Evofem Biosciences, Inc.EVFM · Entity 8607	Director	December 21, 2023	December 22, 2023
SERA PROGNOSTICS, INC.SERA · Entity 304	Director	July 10, 2026	July 14, 2026
Syndax Pharmaceuticals IncSNDX · Entity 4578	Director · 10% owner	October 31, 2016	November 02, 2016
Vyome Holdings, IncOBLN · Entity 1824	Director	September 16, 2020	September 18, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bionano Genomics, Inc.

Report date August 21, 2018 · Filed August 21, 2018

Jointly reported with DOMAIN ASSOCIATES, BLAIR JAMES C, DOVEY BRIAN H, VITULLO NICOLE, Halak Brian K

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	140	Reported balance Holding disclosure · report date 2018-08-21 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 140 F1: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 5(b)(iv) of Form 3, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.20 · Expires 2019-05-10	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-08-21 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: The stock options are held by Brian K. Halak and are fully vested. Pursuant to the limited liability company agreement of Domain Associates, LLC, upon exercise 50% of the shares issued will be transferred to Domain Associates, LLC.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.28 · Expires 2019-05-10	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-08-21 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F2: The stock options are held by Brian K. Halak and are fully vested. Pursuant to the limited liability company agreement of Domain Associates, LLC, upon exercise 50% of the shares issued will be transferred to Domain Associates, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 5(b)(iv) of Form 3, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

F2: The stock options are held by Brian K. Halak and are fully vested. Pursuant to the limited liability company agreement of Domain Associates, LLC, upon exercise 50% of the shares issued will be transferred to Domain Associates, LLC.

Evofem Biosciences, Inc.

Report date December 21, 2023 · Filed December 22, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2023-12-21 transaction · row 1 1 source row Row 1 · 2023-12-21 · Sale · Disposed 10 · Balance 0

SERA PROGNOSTICS, INC.

Report date July 10, 2026 · Filed July 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	58,420	Ending reported balance After 2026-07-10 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-07-10 · Grant · Acquired 22,426 · Balance 54,999 F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Row 2 · 2026-07-10 · Grant · Acquired 3,421 · Balance 58,420 F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10	Direct	34,494	Reported balance After 2026-07-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-07-10 · Grant · Acquired 34,494 · Balance 34,494 F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10	Direct	5,263	Reported balance After 2026-07-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-07-10 · Grant · Acquired 5,263 · Balance 5,263 F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

Syndax Pharmaceuticals Inc

Report date October 31, 2016 · Filed November 02, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.81 · Expires 2026-10-31	Direct	8,000	Reported balance After 2016-10-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-10-31 · Grant · Acquired 8,000 · Balance 8,000

Vyome Holdings, Inc

Report date September 16, 2020 · Filed September 18, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Expires 2030-09-16	Direct	27,250	Reported balance After 2020-09-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-09-16 · Grant · Acquired 27,250 · Balance 27,250 F1: Each share of Common Stock underlying the cash-settled Option represents the right to a cash payment equal to the excess, if any, of (i) the Fair Market Value of each such share on the date of exercise over (ii) the exercise price per share set forth in the Notice of Stock Option Grant ($0.77), and such Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. This Option may not be exercised for shares of the Company's Common Stock. F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2030-09-16	Direct	27,250	Reported balance After 2020-09-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-09-16 · Grant · Acquired 27,250 · Balance 27,250 F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Common Stock underlying the cash-settled Option represents the right to a cash payment equal to the excess, if any, of (i) the Fair Market Value of each such share on the date of exercise over (ii) the exercise price per share set forth in the Notice of Stock Option Grant ($0.77), and such Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. This Option may not be exercised for shares of the Company's Common Stock.

F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Ocera Therapeutics, Inc.

Report date December 11, 2017 · Filed December 13, 2017

Jointly reported with DOMAIN ASSOCIATES, BLAIR JAMES C, DOVEY BRIAN H, TREU JESSE I, VITULLO NICOLE, Halak Brian K

Section 16 reporting ended · disclosed 2017-12-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-12-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-12-11 · Disposition to issuer · Disposed 47,963 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between the Issuer, MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between the Issuer, MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes.

F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Singular Genomics Systems, Inc.

Report date February 21, 2025 · Filed February 25, 2025

Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-02-21 transaction · row 1 1 source row Row 1 · 2025-02-21 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Domain Partners IX, L.P.	Reported balance After 2025-02-21 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-02-21 · Disposition to issuer · Disposed 3,763,985 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). F2: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity; however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.
Common StockSEC Table I · non-derivative	IndirectBy Domain Associates, LLC	Reported balance After 2025-02-21 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2025-02-21 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). F2: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity; however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $672.90 · Expires 2031-05-05	Direct	Reported balance After 2025-02-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-02-21 · Disposition to issuer · Disposed 666 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.80 · Expires 2032-05-26	Direct	Reported balance After 2025-02-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-02-21 · Disposition to issuer · Disposed 1,541 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.80 · Expires 2033-05-25	Direct	Reported balance After 2025-02-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2034-05-29	Direct	Reported balance After 2025-02-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").

F2: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity; however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

Tobira Therapeutics, Inc.

Report date November 01, 2016 · Filed November 04, 2016

Jointly reported with DOMAIN ASSOCIATES, BLAIR JAMES C, DOVEY BRIAN H, TREU JESSE I, VITULLO NICOLE, Halak Brian K

Section 16 reporting ended · disclosed 2016-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-11-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2016-11-01 · Other · Disposed 38,094 · Balance 0 F1: Pursuant to the terms of a merger agreement, pursuant to which the Issuer was acquired by Allergan Holdco US, Inc., the shares were tendered for $28.35 per share in cash plus one non-transferable contingent value right per share, which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones. F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly benefically owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.00	IndirectHeld by Jesse I. Treu	Reported balance After 2016-11-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-11-01 · Disposition to issuer · Acquired 1,996 · Balance 0 F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.93	IndirectHeld by Jesse I. Treu	Reported balance After 2016-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-11-01 · Disposition to issuer · Acquired 1,071 · Balance 0 F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.19	IndirectHeld by Jesse I. Treu	Reported balance After 2016-11-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-11-01 · Disposition to issuer · Acquired 17,695 · Balance 0 F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of a merger agreement, pursuant to which the Issuer was acquired by Allergan Holdco US, Inc., the shares were tendered for $28.35 per share in cash plus one non-transferable contingent value right per share, which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones.

F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly benefically owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger.

F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 09, 2017 Filed May 11, 2017 20:07 UTC	Vyome Holdings, Inc OBLN · Entity 1824	GrantStock Option (Right to Buy) · Derivative	21,000	$0.00 Strike: $11.56	$0.00	Disclosure SEC source: 0000904454-17-000339 · edgar.xml · derivative · entry 1 Kamdar Kim P. · CIK 0001535065 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: The option vests as to 2.777% of the total shares monthly, commencing on June 9, 2017, with 100% of the total shares vested on May 9, 2020, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
November 09, 2016 Filed Nov 14, 2016 22:45 UTC	Vyome Holdings, Inc OBLN · Entity 1824	GrantStock Option (Right to Buy) · Derivative	46,500	$0.00 Strike: $8.74	$0.00	Disclosure SEC source: 0000904454-16-001554 · edgar.xml · derivative · entry 1 Kamdar Kim P. · CIK 0001535065 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 46,500 shares Expires 2026-11-09 F1 · derivative.exercise_date: The option vests monthly over 36 months beginning on 12/09/2016 and will be fully vested on 11/09/2019. Read SEC document
November 01, 2016 Filed Nov 4, 2016 08:30 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerStock Option (Right to Buy) · Derivative	17,695	Not disclosed Strike: $8.19	Not disclosed	Disclosure SEC source: 0000904454-16-001535 · edgar.xml · derivative · entry 4 DOMAIN ASSOCIATES · CIK 0001020733 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Kamdar Kim P. · CIK 0001535065 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Jesse I. Treu Disclosed balance after: 0 Underlying: Common Stock · 17,695 shares Expires not disclosed F3 · price: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4 · price: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger. F3 · derivative.exercise_date: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4 · derivative.exercise_date: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger. F3 · derivative.expiration_date: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4 · derivative.expiration_date: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger. Read SEC document
November 01, 2016 Filed Nov 4, 2016 08:30 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerStock Option (Right to Buy) · Derivative	1,071	Not disclosed Strike: $42.93	Not disclosed	Disclosure SEC source: 0000904454-16-001535 · edgar.xml · derivative · entry 3 DOMAIN ASSOCIATES · CIK 0001020733 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Kamdar Kim P. · CIK 0001535065 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Jesse I. Treu Disclosed balance after: 0 Underlying: Common Stock · 1,071 shares Expires not disclosed F3 · price: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4 · price: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger. F3 · derivative.exercise_date: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4 · derivative.exercise_date: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger. F3 · derivative.expiration_date: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4 · derivative.expiration_date: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger. Read SEC document
November 01, 2016 Filed Nov 4, 2016 08:30 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerStock Option (Right to Buy) · Derivative	1,996	Not disclosed Strike: $36.00	Not disclosed	Disclosure SEC source: 0000904454-16-001535 · edgar.xml · derivative · entry 2 DOMAIN ASSOCIATES · CIK 0001020733 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Kamdar Kim P. · CIK 0001535065 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Jesse I. Treu Disclosed balance after: 0 Underlying: Common Stock · 1,996 shares Expires not disclosed F3 · price: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4 · price: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger. F3 · derivative.exercise_date: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4 · derivative.exercise_date: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger. F3 · derivative.expiration_date: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4 · derivative.expiration_date: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger. Read SEC document
November 01, 2016 Filed Nov 4, 2016 08:30 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	OtherCommon Stock	38,094	$28.35	$1,079,964.90	Disclosure SEC source: 0000904454-16-001535 · edgar.xml · nonDerivative · entry 1 DOMAIN ASSOCIATES · CIK 0001020733 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Kamdar Kim P. · CIK 0001535065 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of a merger agreement, pursuant to which the Issuer was acquired by Allergan Holdco US, Inc., the shares were tendered for $28.35 per share in cash plus one non-transferable contingent value right per share, which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones. F2 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly benefically owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Read SEC document
October 31, 2016 Filed Nov 2, 2016 20:44 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	8,000	$0.00 Strike: $11.81	$0.00	Disclosure SEC source: 0000904454-16-001523 · edgar.xml · derivative · entry 1 Kamdar Kim P. · CIK 0001535065 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-10-31 Read SEC document
October 12, 2016 Filed Oct 14, 2016 15:47 UTC	Vyome Holdings, Inc OBLN · Entity 1824	PurchaseCommon Stock	13,400	$15.00	$201,000.00	Disclosure SEC source: 0000904454-16-001498 · edgar.xml · nonDerivative · entry 1 Kamdar Kim P. · CIK 0001535065 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,400 F1 · ownership.direct: Shares held jointly with the Reporting Person's mother. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.